Gantenerumab in Early Alzheimer's Disease. Reply
N Engl J Med
.
2024 Feb 29;390(9):867.
doi: 10.1056/NEJMc2314291.
Authors
Randall J Bateman
1
,
Janice Smith
2
,
Rachelle S Doody
3
;
GRADUATE I and II Investigators and the Gantenerumab Study Group
Affiliations
1
Washington University School of Medicine, St. Louis, MO batemanr@wustl.edu.
2
Roche Products, Welwyn Garden City, United Kingdom.
3
F. Hoffmann-La Roche, Basel, Switzerland.
PMID:
38416440
DOI:
10.1056/NEJMc2314291
No abstract available
Publication types
Letter
Comment
MeSH terms
Alzheimer Disease* / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Substances
gantenerumab
Antibodies, Monoclonal, Humanized